Peter Forsberg, MD

Peter Forsberg, MD, discusses the importance of data from the MajesTEC-3 trial in mulitple myeloma, in addition to the next steps for the coMMit Consortium.

Drs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.

Drs Forsberg and Lipe discuss strategies for sequencing therapies in relapsed/refractory multiple myeloma.

Peter Forsberg, MD, offers insight into which patients with multiple myeloma are most suitable for treatment with the DARA-Kd regimen.

Brea Lipe, MD, and Peter Forsberg, MD, review the results of the CANDOR trial evaluating DARA-Kd regimen in R/R multiple myeloma.

Brea Lipe, MD, and Peter Forsberg, MD, present the profile of a woman with relapsed/refractory multiple myeloma and share their opinions of the treatment regimen.

Dr Brea Lipe explains at what stages she orders genetic testing in patients with relapsed/refractory multiple myeloma and how she approaches the treatment of patients with high-risk cytogenetics.

Oncologists debate which patient populations most benefit from isatuximab plus carfilzomib and dexamethasone.

Dr Forsberg details the safety data and toxicity management strategies of the IKEMA clinical trial.

Dr Peter Forsberg reviews clinical trial data on a triplet treatment regimen for relapsed/refractory multiple myeloma.

An overview of the available treatment options in relapsed/refractory multiple myeloma.

Brea Lipe, MD, and Peter Forsberg, MD, present the profile of a woman with multiple myeloma in early relapse and discuss their treatment strategy.